Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Keep up the pump gump...it's what you're paid for...
With graphics?
gump..keep pumping.
RB responds to organized TOS campaigns without thinking - they don't have anyone left on customer service.
There is no appeal, but if you want to complain to the customer service manager, Jaime Carney, PM me. Carney doesn't like his e-mail address being published, and calls IHub and SI to have my post deleted whenever I publish it it.
Odd behavior for a customer service manager...
Getting mean and nasty again gump?
No surprise there.
WHO is "Dr. J. DeCosta"? Is he the dentist, James DeCosta, or is he a figment of someone's imagination?
What are the "books" he is supposed to have written?
Isn't it odd that those "SEC letter" extracts are repeatedly posted on RB's GMXX board by gump's cronies but there has been NO answer to the simple questions -
WHO is "Dr. Jim DeCosta"?
What are the "books" he is supposed to have written?
Getting straight answers to those questions shouldn't be like pulling hens' teeth.
Please don't enlighten them...
They obviously haven't figured out the difference between retail days and wholesale days.
WHOIS whois.registersite.com httddirect.com:
Register Your Domain Name at <a href="http://www.registersite.com/?source=whois">RegisterSite.com</a> Today!
HTTD
B100 panchsheel Enclave
1885 SW 4th Ave. #
E3 Delray Delray
Florida, Florida 34444
US
Domain name: HTTDDIRECT.COM
Administrative Contact:
Das, Navanil navanil@yahoo.com
160-16 Booth Memorial AVe
Flushing, NY 11365
US
+1.7184638570 Fax: +1.7184638570
Technical Contact:
Das, Navanil navanil@yahoo.com
160-16 Booth Memorial AVe
Flushing, NY 11365
US
+1.7184638570 Fax: +1.7184638570
Account for domain www.httddirect.com has been suspended
ICI / NAANS / Genemax:
Investor Communications International (ICI) is a stock promotion firm that has been the most vocal critic of naked short selling. ICI has formed the National Association Against Naked Short Selling (NAANSS) which has been lobbying in Washington DC against naked short selling. On their website (http://www.nakedshortselling.com ), they ask people to join their organization in order to "make your voice heard in Washington, D.C.". ICI and its associated companies have issued numerous press releases complaining about manipulation by naked short sellers, but have never presented any evidence to back up these claims.
In a recent SEC filing, the president of ICI is listed as Brent Pierce (filing DEF 14C for Petrogen Corp issued on 12/31/02 http://www.sec.gov/Archives/edgar/data/1057226/000105050202001084/hadro- def14c.txt ). Pierce was found to have committed securities fraud by the British Columbia Securities Commission and was "prohibited from becoming or acting as a director or officer of any reporting issuer for a period of 15 years" (http://www.bcsc.bc.ca/Enforcement/eol/pierce_gordon.htm).
ICI is well known for its close ties to the biotech company Genemax (BB:GMXX). ICI brought Genemax public, performs investor relations for it, and is a large shareholder. ICI and Genemax also share the same address in Blaine, WA, and share various officers and consultants. Genemax and ICI launched a widely publicized campaign against naked short sellers last year when Genemax tried to exit the Depository Trust Corporation (DTC) and have its shares trade only as paper certificates in an effort to prevent naked short selling of their stock. Excitement over this tactic caused shares of Genemax to soar from about $1.00 per share to over $20.00 (and then back to $1.00), and ICI persuaded dozens of other companies to attempt to leave the DTC. These companies claimed that naked short selling was depressing the price of their stock, but did not present any evidence that this was indeed true. The SEC ultimately did not allow these companies to go to trading of paper certificates.
James D. Davidson, until recently CFO, director, and a shareholder of Genemax, is an editor and founder of Agora publishing, which was recently charged by the SEC with stock fraud (http://www.sec.gov/litigation/complaints/comp18090.htm ).
With these types of associations, ICI is not a credible source for complaints about stock manipulation.
http://www.sec.gov/rules/proposed/s72303/ger010504.htm
"Anthony J. Cataldo"
a.k.a.: "Anthony J Cataldo" · "Anthony J.Cataldo"
Latest Filing: 11/14/3 as Signatory
As: Registrant
Cataldo Anthony J
--------------------------------------------------------------------------------
As: Signatory (Director, Officer, Attorney, Accountant, Banker, Agent, etc.)
List All Filings as Signatory
Search Recent Filings (as Signatory) for "Anthony J. Cataldo"
"Anthony J. Cataldo" has been a Signatory for/with the following 6 Registrants:
Brandpartners Group Inc (formerly Financial Performance Corp)
Senetek PLC/ENG
Management Technologies Inc
1st Miracle Group Inc/Ontario
Calypte Biomedical Corp
1st Miracle Entertainment Inc (formerly 1st Miracle Group Inc)
http://www.secinfo.com/$/SEC/Name.asp?S=anthony+j%2Ecataldo
- - - - -
TEI Co-chairman Mohamed Hadid said, "Election of Mr. Zwebner represents another step forward in the restructuring of the Corporation's business plans."
"Tony Cataldo Resigns Position as President of The Entertainment Internet, Inc. (TEI)"
LOS ANGELES, Jan. 14 /PRNewswire/ -- The Entertainment Internet, Inc. (TEI) (OTC Bulletin Board: EINIE)
The Entertainment Internet, Inc. Elects Michael Zwebner To Board of Directors
Business/Entertainment Editors
LOS ANGELES--(BUSINESS WIRE)--June 28, 2000--The Entertainment Internet, Inc. (TEI) (EQS:EINI) confirmed today the election of Michael J. Zwebner to its Board of Directors.
Zwebner currently serves as the Chairman of the Board of Directors of Talk Visual Corporation (OTCBB:TVCP) and earlier offered to assist TEI in furthering the turnaround plan undertaken last year.
TEI Co-chairman Mohamed Hadid said, "Election of Mr. Zwebner represents another step forward in the restructuring of the Corporation's business plans."
Prior to his election, Zwebner conducted due diligence inquiries that included review of the corporation's capital structure, prior transactions, current commitments, and interviews with subsidiary corporation staff. Throughout the due diligence process, Zwebner retained his belief that TEI has not yet realized more than a fraction of its potential and that he could assist in moving TEI toward its profit-making goals.
TEI Chief Operating Officer Jeremy Schuster said, "Mr. Zwebner understands the roles of e-commerce and strategic relationships in our new business model; his years of marketing experience can only complement the initiative we undertook last July. The Board welcomes Mr. Zwebner and looks forward to his continued involvement."
Currently, TEI's subsidiary operates the Castnet.com(TM) electronic communities that help actors, casting directors and talent agents electronically communicate with each other and receive instant responses to specialized data searches. TEI's Castnet.com(TM) systems provide users with access to a sophisticated virtual private network that offers security, performance and reliability matched to the needs of the entertainment industry.
TEI's database resources and Castnet.com(TM) services are used by more than 300 casting directors, 185 guild franchised agencies and 32,000 actors across the United States, with additional subscribers being added daily. The Castnet.com sites have the approval of the Producers Guild of America.
Tony Cataldo Resigns Position as President of The Entertainment Internet, Inc. (TEI)
LOS ANGELES, Jan. 14 /PRNewswire/ -- The Entertainment Internet, Inc. (TEI) (OTC Bulletin Board: EINIE) announced today that the resignation of Mr. Tony Cataldo, earlier offered in conjunction with cancellation of a proposed TEI-Miracle Entertainment (OTC Bulletin Board: MVEE) merger, was accepted by TEI's Board of Directors. Mr. Cataldo served as TEI President and a member of its Board of Directors. TEI Chief Operating Officer Jeremy Schuster said TEI and Miracle Entertainment will continue to work together through earlier-executed casting agreements.
December, 1999
http://snipurl.com/3uja
Amended Consulting Agreement - Keith Lippert
http://www.secinfo.com/drdbh.223v.3.htm
Exhibit 4.1(j)
Amendment 1 to Consulting Agreement
Between Calypte Biomedical Corporation and Keith Lippert
This Agreement amends and modifies the Consulting Agreements between Calypte Biomedical Corporation (“Calypte” or the “Company”) and Lippert/Heilshorn & Associates/Keith Lippert (“Consultant”) and is effective as of March 26, 2003.
Whereas, the Company desires to change the payment terms on the contract for certain consulting services performed in 2002 and 2003 and Consultant is agreeable to such modification.
Now therefore, in consideration of the premises and mutual promises set forth herein, the parties hereto agree as follows:
1. The Company acknowledges that as of March 26, 2003 it owes Consultant certain amounts for services rendered, payable in cash. It will now convert this payment to stock issuable to Consultant individually, or his designee, a total of 1,650,000 shares in full payment due under the contract and related notice period.
2. In consideration for this modification, the Company agrees to register the shares with the upcoming S-8 filing during March 2003. If the filing occurs after March, Consultant has the option to accept only cash.
3. All other terms and conditions of the 2002 Consultant Agreements remain unchanged.
Consultant:
Calypte Biomedical Corporation
/s/ Keith Lippert
--------------------------------------------------------------------------------
By:
/s/ Richard D. Brounstein
--------------------------------------------------------------------------------
Keith Lippert
Richard D. Brounstein
Executive Vice President, CFO
Amended Consulting Agreement - Denise Lescasse-Laurent
http://www.secinfo.com/drdbh.223v.4.htm
Exhibit 4.1(i)
Amendment 1 to Consulting Agreements
Between Calypte Biomedical Corporation and Denise Lescasse-Laurent
This Agreement amends and modifies the Consulting Agreements between Calypte Biomedical Corporation (“Calypte” or the “Company”) and SARL MAJESTIC/Denise Lescasse-Laurent (“Consultant”) and is effective as of March 25, 2003.
Whereas, the Company desires to change the payment terms on the contract for certain consulting services performed in 2002 and 2003 and Consultant is agreeable to such modification.
Now therefore, in consideration of the premises and mutual promises set forth herein, the parties hereto agree as follows:
1. The Company acknowledges that as of March 25, 2003 it owes Consultant $19,772.42 for services rendered, payable in cash. It will now convert these payments to stock issuable to Consultant based on a value of approximately $0.025 per share for a total of 791,000 shares.
2. In consideration for this modification, the Company agrees to register the shares with the upcoming S-8 filing during March 2003. If the filing occurs after March, Consultant has the option to accept only cash.
3. All other terms and conditions of the 2002 Consultant Agreements remain unchanged.
Consultant:
Calypte Biomedical Corporation
/s/ Denise Lescasse-Laurent
--------------------------------------------------------------------------------
By:
/s/ Richard D. Brounstein
--------------------------------------------------------------------------------
Denise Lescasse-Laurent
Richard D. Brounstein
Executive Vice President, CFO
Amended Consulting Agreement - Michael Sitrick
http://www.secinfo.com/drdbh.223v.5.htm
Exhibit 4.1(h)
Amendment 1 to Consulting Agreement
Between Calypte Biomedical Corporation and Sitrick
This letter (“Letter”) when accepted by you as provided below will modify and amend the referenced engagement letter (the “Engagement Letter”) between Sitrick And Company Inc., a California Corporation and its Principal, Michael Sitrick (“Sitrick”), and Calypte Biomedical Corporation, a Delaware corporation (“Calypte” or the “Company”).
Pursuant to the Engagement Letter Sitrick was retained to provide certain consulting and other services (the “Services”) to the Company (the “Engagement”). The Engagement was terminated by Calypte effective as of October 25, 2002, at which time Calypte was indebted to Sitrick for unpaid fees related to Services rendered by Sitrick pursuant to the Engagement Letter plus expenses Sitrick incurred through that date (the “Debt”). As part of Sitrick’s compensation under the Engagement Letter, Calypte was to issue to Sitrick, and cause to be registered under the Securities Act of 1933 as amended, as freely-tradable, 300,000 shares of its Common Stock (the “Shares”) which Shares have been issued to Sitrick but not registered.
The parties now wish to reinstate the Engagement and have Sitrick resume providing the Services, pursuant to the terms and conditions of the Engagement Letter as modified by this Letter, and to fully and finally settle all differences related to the Debt and the Shares.
Effective as of March 26, 2003, the parties reinstate the Engagement pursuant to the Engagement Letter, including the previously agreed-upon monthly retainer of $7,500 plus expenses for investor relations consulting services (“IR Services”). The Company acknowledges the $7,500 is the minimum, non-refundable monthly fee retainer for Sitrick’s IR Services. The Company further acknowledges that for IR Services: (i) Sitrick’s time charges will be billed against the retainer at the hourly rate range of $160 to $625, depending on the person performing the services; (ii) when the $7,500 monthly retainer has been fully applied against that month’s time charges, additional time charges for the month will be billed as incurred; (iii) time charges are computed on a portal-to-portal basis for any travel time for meetings held outside of Sitrick’s offices; (iv) time is charged and billed by Sitrick in increments of one-quarter of an hour; and (v) hourly rates are adjusted at the end of each calendar year.
The Company also acknowledges and Sitrick agrees that Sitrick shall be compensated for any fees related to IR Services (based on time charges) incurred in a month that exceed the $7,500 monthly retainer, provided Sitrick has received prior approval from Calypte to perform additional services. The $7,500 monthly retainer shall be due and payable on or prior to the first day of the calendar month to which it relates. Fees billed in excess of the retainer for that month shall be due and payable within twenty days of invoice date. The retainer for March 2003 will be prorated as of the effective date of this Letter and payment made within three business days.
The $7,500 monthly retainer is to cover time charges for IR Services and is not to cover time charges for extraordinary projects as defined in the Engagement Letter. As with IR Services, the Company acknowledges that for extraordinary projects (i) Sitrick’s time charges will be billed at the hourly rate range of $160 to $625, depending on the person performing the services, (ii) time charges are computed on a portal-to-portal basis for any travel time for meetings held outside of Sitrick’s offices; (iii) time is charged and billed by Sitrick in increments of one-quarter of an
hour; and (iv) hourly rates are adjusted at the end of each calendar year. Time charges will be billed as incurred and shall become due and payable within twenty days of invoice date.
Payment for out of pocket expenses for Services remains as per the Engagement Letter.
Calypte acknowledges it has not registered the Shares as freely-tradable as required by the Engagement Letter and that the Debt, which is due, owing and payable to Sitrick without offset, totals $35,264.34 (comprised of $29,495.64 for past investor relations consulting services plus $5,768.70 for services on the extraordinary project related to the preparation of a public service announcement). Calypte agrees to settle the Debt and to register the Shares in accordance with the following terms:
(i) Calypte shall at its sole cost and expense cause the Shares to be registered under the Securities Act of 1933 as amended by filing an S-8 with the Securities and Exchange Commission on or before March 28, 2003 or in lieu thereof, shall cause a like number of shares to be registered and issued to Sitrick by March 28, 2003 in exchange for the original Shares;
(ii) Calypte acknowledges that it owes and shall satisfy the Debt ($35,264.34) through the issuance to Michael Sitrick, principal, or his assignee, of 1,500,000 registered, freely-tradable shares of Calypte Common Stock on or before March 28, 2003;
(iii) In the event the 1,500,000 shares are not registered by March 28, 2003 as required by (ii) above, then the full amount ($35,264.34) of the Debt shall be immediately due and payable in cash, plus interest at the rate of 10% per annum from the date the amounts were past due.
Except as modified by this Letter, the Engagement Letter is reinstated and operative without modification or amendment.
SITRICK AND COMPANY INC.
CALYPTE BIOMEDICAL CORPORATION
Agreed and accepted
By
/s/ Michael Sitrick
--------------------------------------------------------------------------------
By
/s/ Richard D. Brounstein
--------------------------------------------------------------------------------
Michael Sitrick
Chairman and CEO
Richard D. Brounstein
Executive Vice President and CFO
Amended Consulting Agreement - Ronald Mink
http://www.secinfo.com/drdbh.223v.6.htm
Exhibit 4.1(g)
Amendment 1 to Consulting Agreement
Between Calypte Biomedical Corporation and Ronald W. Mink
This Agreement amends and modifies the Consulting Agreement between Calypte Biomedical Corporation (“Calypte” or the “Company”) and Creative BioSolutions/Ron Mink (“Consultant”) dated July 15, 2002 and is effective as of March 24, 2003.
Whereas, the Company desires to change the payment terms on the contract and Consultant is agreeable to such modification.
Now therefore, in consideration of the premises and mutual promises set forth herein, the parties hereto agree as follows:
1. The Company acknowledges that it owes Consultant $28,264.21 for services rendered, payable in cash. It will now convert these payments to stock issuable to Consultant based on a value of approximately $0.025 per share for a total of 1,131,000 shares.
2. In consideration for this modification, the Company agrees to register the shares with the upcoming S-8 filing during March 2003. If the filing occurs after March, Consultant has the option to accept only cash.
3. Further, the remaining shares included in the initial agreement as a stock bonus are now considered fully vested.
4. All other terms and conditions of the Consultant Agreement dated July 15, 2002 remain unchanged.
Consultant:
Calypte Biomedical Corporation
/s/ Ronald W. Mink
--------------------------------------------------------------------------------
By:
/s/ Richard D. Brounstein
--------------------------------------------------------------------------------
Ronald W. Mink
Richard D. Brounstein
Executive Vice President, CFO
Consulting Agreement - Cliff Brune
http://www.secinfo.com/drdbh.223v.7.htm
Exhibit 4.1(f)
Consulting Agreement of March 14, 2003
March 14, 2003
Mr. Anthony J. Cataldo
Executive Chairman
Calypte Biomedical Corporation
1265 Harbor Bay Parkway
Alameda, CA 94502
Dear Tony,
As a result of our most recent conversation regarding the status of Calypte and your plans to effect a reorganization and downsizing, I submit this letter to serve as my resignation, effective immediately. I will consult for the company in a transition role for the next 30 days. This resignation letter is being provided at your request, subject to the previous obligations of the company noted below, as any termination by you would require 30 days proper written notice as provided by our employment agreement dated January 2, 2003.
The agreement also provided for 200,000 fully vested options, which I have not been issued. I am hereby requesting and you agree, that in lieu of this, 240,000 fully vested warrants at .025 (two and one half cents) and with a term of 1 year be granted and be provided immediately, for services that I will provide as a consultant. You further agree to register these with the upcoming S-8 filing during March 2003.
Further, I have submitted and approved expenses outstanding totaling $2591.76, which are due and payable immediately.
This resignation is being tendered only with the understanding that you will, by March 21, 2003, satisfy the outstanding obligations noted above. In the event they are not satisfied by this date, the resignation will not be in effect, and the company will be bound by the 30- day proper written notice requirement and any and all other obligations provided for in the employment agreement.
As a shareholder, I continue to wish the Company and its employees the best, and trust your plans for its future are successful.
Respectfully,
/s/ Cliff Brune
Cliff Brune
Agreed and Accepted: /s/ Richard D. Brounstein
Richard Brounstein, Calypte CFO
Amended Consulting Agreement - Hendrix Bodden
http://www.secinfo.com/drdbh.223v.8.htm
Exhibit 4.1(e)
Amendment to Consulting Agreement of September 24, 2002
February 17, 2003
Mr. Hendrix H. Bodden
Principal
Strategic Business Initiatives
1700 California Ave Suite 601
San Francisco, California 94109
Dear Mr. Bodden,
The within is to confirm our understanding and agreement as February 17, 2003 wherein Strategic Business Systems (SBI) and their principal, Hendrix Bodden, have agreed to settle amounts owed by Calptye Biomedical Corporation (the Company) under the previously executed Professional Services Agreement and Calypte Biomedical IT Project Statement of Work both dated September 4, 2002.
Whereas the Terms and Conditions section of the Statement of Work provided for payment of seven installments totaling $335,000 of which the Company has satisfied three installments for a total of $155,000, leaving an unpaid balance of $180,000.
In consideration for settlement of the outstanding balance of $180,000, the Company agrees to pay SBI the sum of $45,000 in cash and to issue to SBI’s principal one million shares of Calptye Biomedical Corporation non-assessable and fully paid common stock $.001 par value. SBI understands that the shares are unregistered and restricted and the Company agrees to provide cost free piggy-back registration rights. SBI may elect to have said shares replaced with shares from the Company Stock Option Plan, in the event that shares in the Stock Option Plan become approved, available and free trading prior to the effective registration provided by the piggy-back registration rights.
The Company also agrees to pay approved and outstanding expenses totaling $2906.66, on or before February 21, 2003, for a total cash payment of $47,906.66.
SBI agrees to provide the Company a final detailed copy of the Requirements Definition and Implementation Matrix as contemplated under the Statement of Work on or before February 21, 2003.
Both the Company and SBI mutually agree that, subject to the above, all deliverables and amounts due as contemplated by the agreements have been satisfied in their entirety. --------------------------------------------------------------------------------
The Company and SBI further agree that all information regarding this settlement and agreement are to remain confidential.
If the within meets with your understanding and agreement, please execute a copy of same.
Very truly yours,
CALPTYE BIOMEDICAL CORPORATION
/s/ Anthony J. Cataldo
Anthony J. Cataldo
Executive Chairman
Agreed To:
STRATEGIC BUSINESS INITIATIVES
/s/ Hendrix Bodden
Hendrix H. Bodden
Principal
Consulting Agreement - Mohamed Hadid
http://www.secinfo.com/drdbh.223v.9.htm
Exhibit 4.1(d)
CONSULTING AGREEMENT
AGREEMENT, effective as of the 27th day of March, 2003, between Calypte Biomedical Corporation, a Delaware Corporation (the “Company”), of 1265 Harbor Parkway, Alameda, CA 94502, and Mohamed Hadid, 100 Carolwood, Los Angeles, CA 90077 (“Consultant”).
WHEREAS, THE Company desires the Consultant to provide consulting services to the Company pursuant hereto and Consultant is agreeable to providing such services.
NOW THEREFORE, in consideration of the premises and the mutual promises set forth herein, the parties hereto agree as follows:
1. Consultant shall serve as a consultant to assist the Company in general corporate activities including but not limited to the following areas:
(a) Research venues for foreign sales for the company’s products.
(b) Assist in the establishment of distribution partners in the Middle East and Russia for the company’s products.
(c) Provide support, including competitive information, for these regions.
2. Term: The Company shall be entitled to Consultant’s services for reasonable times when and to the extent requested by, and subject to the direction of Mr. Cataldo. The term of this Consulting Agreement began as of the date of this Agreement, and shall terminate on May 27, 2003.
3. Reasonable travel and other expenses necessarily incurred by Consultant to render such services, and approved in advance by the Company, shall be reimbursed by the Company promptly upon receipt of proper statements, including appropriate documentation, with regard to the nature and amount of those expenses. Those statements shall be furnished to the Company monthly at the end of each calendar month in the Consulting Period during which any such expenses are incurred. Company shall pay expenses within fifteen (15) business days of the receipt of a request with appropriate documentation.
4. In consideration for the services to be performed by Consultant, the Consultant will receive a warrant to purchase eight million, (8,000,000) shares of the common stock of the Company at an exercise price of $0.025 cents per share. The warrant expires on June 27, 2003.
--------------------------------------------------------------------------------
5. The consultant will provide to Calypte’s Executive Chairman a written report of services rendered and results thereof within 30 days of the conclusion of this contract.
6. It is the express intention of the parties that the Consultant is an independent contractor and not an employee or agent of the Company. Nothing in this agreement shall be interpreted or construed as creating or establishing the relationship of employer and employee between the Consultant and the Company. Both parties acknowledge that the Consultant is not an employee for state or federal tax purposes. The Consultant shall retain the right to perform services for others during the term of this agreement.
6.1 The consulting services shall not involve and the consultant is not engaged in services in connection with the offer or sale of securities in a capital-raising transaction for Calypte, and further, the consultant does not and will not directly or indirectly promote or maintain a market for Calypte’s securities.
7. Neither this agreement nor any duties or obligations under this agreement may be assigned by the Consultant without the prior written consent of the Company.
8. This agreement may be terminated upon ten (10) days written notice by the Company. Notwithstanding any termination, the compensation, as outlined in Section 4, shall be earned in full by the Consultant upon execution of this agreement.
9. Any notices to be given hereunder by either party to the other may be given either by personal delivery in writing or by mail, registered or certified, postage prepaid with return receipt requested. Mailed notices shall be addressed to the parties at the addressed appearing in the introductory paragraph of this agreement, but each party may change the address by written notice in accordance with the paragraph. Notices delivered personally will be deemed communicated as of actual receipt; mailed notices will be deemed communicated as of two days after mailing.
10. This agreement supersedes any and all agreements, either oral or written, between the parties hereto with respect to the rendering of services by the Consultant for the Company and contains all the covenants and agreements between the parties with respect to the rendering of such services in any manner whatsoever. Each party to
this agreement acknowledges that no representations, inducements, promises, or agreements, orally or otherwise, have been made by any party, or anyone acting on behalf of any party, which are not embodied herein, and that no other agreement, statement, or promise not contained in this agreement shall be valid or binding. Any modification of this agreement will be effective only if it is in writing signed by the party to be charged.
11. This agreement will be governed by and construed in accordance with the laws of the State of California, without regard to its conflicts of laws provisions; and the parties agree that the proper venue for the resolution of any disputes hereunder shall be Alameda County, California.
12. For purposes of this Agreement, Intellectual Property will mean (i) works, ideas, discoveries, or inventions eligible for copyright, trademark, patent or trade secret protection; and (ii) any applications for trademarks or patents, issued trademarks or patents, or copyright registrations regarding such items. Any items of Intellectual Property discovered or developed by the Consultant (or the Consultant’s employees) during the term of this Agreement will be the property of the Consultant, subject to the irrevocable right and license of the Company to make, use or sell products and services derived from or incorporating any such Intellectual Property without payment of royalties. Such rights and license will be exclusive during the term of this Agreement, and any extensions or renewals of it. After termination of this Agreement, such rights and license will be nonexclusive, but will remain royalty-free. Notwithstanding the preceding, the textual and/or graphic content of materials created by the Consultant under this Agreement (as opposed to the form or format of such materials) will be, and hereby are, deemed to be “works made for hire” and will be the exclusive property of the Company. Each party agrees to execute such documents as may be necessary to perfect and preserve the rights of either party with respect to such Intellectual Property.
13. The written, printed, graphic, or electronically recorded materials furnished by the Company for use by the Consultant are Proprietary Information and are the property of the Company. Proprietary Information includes, but is not limited to, product specifications and/or designs, pricing information, specific customer requirements, customer and potential customer lists, and information on Company’s employees, agent, or divisions. The Consultant shall maintain in confidence and shall not, directly or indirectly, disclose or use, either during or after the term of this agreement, any Proprietary Information, confidential information, or know-how belonging to the Company, whether or not is
in written form, except to the extent necessary to perform services under this agreement. On termination of the Consultant’s services to the Company, or at the request of the Company before termination, the Consultant shall deliver to the Company all material in the Consultant’s possession relating to the Company’s business.
14. The obligations regarding Proprietary Information extend to information belonging to customers and suppliers of the Company about which the Consultant may have gained knowledge as a result of performing services hereunder.
15. The Consultant shall not, during the term of this agreement and for a period of one year immediately after the termination of this agreement, or any extension of it, either directly or indirectly (a) for purposes competitive with the products or services currently offered by the Company, call on, solicit, or take away any of the Company’s customers or potential customers about whom the Consultant became aware as a result of the Consultant’s services to the Company hereunder, either for the Consultant or for any other person or entity, or (b) solicit or take away or attempt to solicit or take away any of the Company’s employees or consultants either for the Consultant or for any other person or entity.
16. The Company will indemnify and hold harmless Consultant from any claims or damages related to statements prepared by or made by Consultant that are either approved in advance by the Company or entirely based on information provided by the Company.
Consultant:
Mohamed Hadid
Company:
Calypte Biomedical Corporation
/s/ Mohamed Hadid
--------------------------------------------------------------------------------
By:
/s/ Richard Brounstein
--------------------------------------------------------------------------------
Richard Brounstein
Executive Vice President & CFO
Amended Consulting Agreement - V.T. Franzke
http://www.secinfo.com/drdbh.223v.a.htm
Exhibit 4.1(c)
Amendment No. 1 to Consulting Agreement
Between Calypte Biomedical Corporation
and V.T. Franzke
This Agreement amends and modifies the Consulting Agreement between Calypte Biomedical Corporation (“Calypte” or the “Company”) and V.T. Franzke (“Consultant”) dated February 14, 2003 and is effective as of March 25, 2003.
Whereas, the Company desires to extend the time period during which Consultant will provide services to the Company pursuant to the above referenced Consulting Agreement and Consultant is agreeable to extending the time for providing such services.
Now therefore, in consideration of the premises and mutual promises set forth herein, the parties hereto agree as follows:
1. The term of Consultant’s Consulting Agreement shall be extended and, by virtue of this Amendment, shall terminate on September 30, 2003 rather than July 14, 2003.
2. In consideration for the extension of the services to be performed by Consultant, the Company will immediately grant to Consultant a warrant to purchase 10,000,000 shares of the registered common stock of the Company at $0.025 per share, or an aggregate purchase price of $250,000. All compensation pursuant to the Consulting Agreement and this Amendment is fully earned upon execution of this amendment. The warrant is immediately exercisable upon grant and will expire on September 30, 2003.
3. The Consultant will provide to Calypte’s Executive Chairman a written report of services rendered and results thereof each 90 days of this extended contract within 30 days of the contract’s quarter end.
4. All other terms and conditions of the Amended Consultant Agreement dated February 14, 2003 remain unchanged.
Consultant:
V.T. Franzke
Company:
Calypte Biomedical Corporation
/s/ V.T. Franzke
--------------------------------------------------------------------------------
By:
/s/ Richard D. Brounstein
--------------------------------------------------------------------------------
V.T. Franzke
Richard Brounstein
EVP & CFO
EX-4.1(B) · Amended Consulting Agreement - George Furla
http://www.secinfo.com/drdbh.223v.b.htm
--------------------------------------------------------------------------------
Amended Consulting Agreement - George Furla
Exhibit 4.1(b)
Amendment No. 2 to Consulting Agreement
Between Calypte Biomedical Corporation
and George Furla
This Agreement amends and modifies the Amended Consulting Agreement between Calypte Biomedical Corporation (“Calypte” or the “Company”) and George Furla (“Consultant”) dated February 14, 2003 and is effective as of March 24, 2003.
Whereas, the Company desires to extend the time period during which Consultant will provide services to the Company pursuant to the above referenced Consulting Agreement and Consultant is agreeable to extending the time for providing such services.
Now therefore, in consideration of the premises and mutual promises set forth herein, the parties hereto agree as follows:
1. The term of Consultant’s Consulting Agreement shall be extended and, by virtue of this Amendment, shall terminate on August 20, 2003 rather than May 20, 2003.
2. In consideration for the extension of the services to be performed by Consultant, the Company will immediately grant to Consultant a warrant to purchase 10,000,000 shares of the registered common stock of the Company at $0.025 per share, or an aggregate purchase price of $250,000. All compensation pursuant to the Consulting Agreement and this Amendment is fully earned upon execution of this amendment. The warrant is immediately exercisable upon grant and will expire on June 24, 2003.
3. The Consultant will provide to Calypte’s Executive Chairman a written report of services rendered and results thereof each 90 days of this extended contract within 30 days of the contract’s quarter end.
4. All other terms and conditions of the Amended Consultant Agreement dated February 14, 2003 remain unchanged.
Consultant:
Calypte Biomedical Corporation
/s/ George Furla
--------------------------------------------------------------------------------
By:
/s/ Richard D. Brounstein
--------------------------------------------------------------------------------
George Furla
Richard Brounstein
Executive Vice President & CFO
Consulting Agreement - Howard Schraub
Exhibit 4.1(a)
http://www.secinfo.com/drdbh.223v.c.htm
CONSULTING AGREEMENT
AGREEMENT, effective as of the 24th day of March, 2003, between Calypte Biomedical Corporation, a Delaware Corporation (the “Company”), of 1265 Harbor Parkway, Alameda, CA 94502, and Howard Schraub, 8638 Rueffe Monte Carlo, La Jolla CA 92037 (“Consultant”).
WHEREAS, THE Company desires the Consultant to provide consulting services to the Company pursuant hereto and Consultant is agreeable to providing such services.
NOW THEREFORE, in consideration of the premises and the mutual promises set forth herein, the parties hereto agree as follows:
1. Consultant shall serve as a consultant to assist the Company in general corporate activities including but not limited to the following areas:
(a) Research venues for foreign sales for the company’s products.
(b) Assist in the foreign marketing of the company’s products.
(c) Assist in locating foreign strategic partners.
2. Term: The Company shall be entitled to Consultant’s services for reasonable times when and to the extent requested by, and subject to the direction of Mr. Cataldo. The term of this Consulting Agreement began as of the date of this Agreement, and shall terminate on June 24, 2003.
3. Reasonable travel and other expenses necessarily incurred by Consultant to render such services, and approved in advance by the Company, shall be reimbursed by the Company promptly upon receipt of proper statements, including appropriate documentation, with regard to the nature and amount of those expenses. Those statements shall be furnished to the Company monthly at the end of each calendar month in the Consulting Period during which any such expenses are incurred. Company shall pay expenses within fifteen (15) business days of the receipt of a request with appropriate documentation.
4. In consideration for the services to be performed by Consultant, the Consultant will receive a warrant to purchase ten million, (10,000,000) shares of the common stock of the Company at an exercise price of $0.025 cents per share. The warrant expires on June 24, 2003.
5. The consultant will provide to Calypte’s Executive Chairman a written report of services rendered and results thereof within 30 days of the conclusion of this contract.
--------------------------------------------------------------------------------
6. It is the express intention of the parties that the Consultant is an independent contractor and not an employee or agent of the Company. Nothing in this agreement shall be interpreted or construed as creating or establishing the relationship of employer and employee between the Consultant and the Company. Both parties acknowledge that the Consultant is not an employee for state or federal tax purposes. The Consultant shall retain the right to perform services for others during the term of this agreement.
6.1 The consulting services shall not involve and the consultant is not engaged in services in connection with the offer or sale of securities in a capital-raising transaction for Calypte, and further, the consultant does not and will not directly or indirectly promote or maintain a market for Calypte’s securities.
7. Neither this agreement nor any duties or obligations under this agreement may be assigned by the Consultant without the prior written consent of the Company.
8. This agreement may be terminated upon ten (10) days written notice by the Company. Notwithstanding any termination, the compensation, as outlined in Section 4, shall be earned in full by the Consultant upon execution of this agreement.
9. Any notices to be given hereunder by either party to the other may be given either by personal delivery in writing or by mail, registered or certified, postage prepaid with return receipt requested. Mailed notices shall be addressed to the parties at the addressed appearing in the introductory paragraph of this agreement, but each party may change the address by written notice in accordance with the paragraph. Notices delivered personally will be deemed communicated as of actual receipt; mailed notices will be deemed communicated as of two days after mailing.
10. This agreement supersedes any and all agreements, either oral or written, between the parties hereto with respect to the rendering of services by the Consultant for the Company and contains all the covenants and agreements between the parties with respect to the rendering of such services in any manner whatsoever. Each party to this agreement acknowledges that no representations, inducements, promises, or agreements, orally or otherwise, have been made by any party, or anyone acting on behalf of any party, which are not embodied
herein, and that no other agreement, statement, or promise not contained in this agreement shall be valid or binding. Any modification of this agreement will be effective only if it is in writing signed by the party to be charged.
11. This agreement will be governed by and construed in accordance with the laws of the State of California, without regard to its conflicts of laws provisions; and the parties agree that the proper venue for the resolution of any disputes hereunder shall be Alameda County, California.
12. For purposes of this Agreement, Intellectual Property will mean (i) works, ideas, discoveries, or inventions eligible for copyright, trademark, patent or trade secret protection; and (ii) any applications for trademarks or patents, issued trademarks or patents, or copyright registrations regarding such items. Any items of Intellectual Property discovered or developed by the Consultant (or the Consultant’s employees) during the term of this Agreement will be the property of the Consultant, subject to the irrevocable right and license of the Company to make, use or sell products and services derived from or incorporating any such Intellectual Property without payment of royalties. Such rights and license will be exclusive during the term of this Agreement, and any extensions or renewals of it. After termination of this Agreement, such rights and license will be nonexclusive, but will remain royalty-free. Notwithstanding the preceding, the textual and/or graphic content of materials created by the Consultant under this Agreement (as opposed to the form or format of such materials) will be, and hereby are, deemed to be “works made for hire” and will be the exclusive property of the Company. Each party agrees to execute such documents as may be necessary to perfect and preserve the rights of either party with respect to such Intellectual Property.
13. The written, printed, graphic, or electronically recorded materials furnished by the Company for use by the Consultant are Proprietary Information and are the property of the Company. Proprietary Information includes, but is not limited to, product specifications and/or designs, pricing information, specific customer requirements, customer and potential customer lists, and information on Company’s employees, agent, or divisions. The Consultant shall maintain in confidence and shall not, directly or indirectly, disclose or use, either during or after the term of this agreement, any Proprietary Information, confidential information, or know-how belonging to the Company, whether or not is in written form, except to the extent necessary to perform services under this agreement. On termination of the Consultant’s services to the Company, or at the request of the Company before termination, the
Consultant shall deliver to the Company all material in the Consultant’s possession relating to the Company’s business.
14. The obligations regarding Proprietary Information extend to information belonging to customers and suppliers of the Company about which the Consultant may have gained knowledge as a result of performing services hereunder.
15. The Consultant shall not, during the term of this agreement and for a period of one year immediately after the termination of this agreement, or any extension of it, either directly or indirectly (a) for purposes competitive with the products or services currently offered by the Company, call on, solicit, or take away any of the Company’s customers or potential customers about whom the Consultant became aware as a result of the Consultant’s services to the Company hereunder, either for the Consultant or for any other person or entity, or (b) solicit or take away or attempt to solicit or take away any of the Company’s employees or consultants either for the Consultant or for any other person or entity.
16. The Company will indemnify and hold harmless Consultant from any claims or damages related to statements prepared by or made by Consultant that are either approved in advance by the Company or entirely based on information provided by the Company.
Consultant:
Howard Schraub
Company:
Calypte Biomedical Corporation
/s/ Howard Schraub
--------------------------------------------------------------------------------
By:
/s/ Richard Brounstein
--------------------------------------------------------------------------------
Richard Brounstein
Executive Vice President & CFO
Calypte Biomedical Corp · S-8 · On 3/28/3 · EX-4.1
SEC File 333-104113 · Accession Number 898430-3-2160
Registration of Securities to be Offered to Employees Pursuant to an Employee Benefit Plan · Form S-8
2: EX-4.1 Advisory and Consulting Agreement
3: EX-4.1(A) Consulting Agreement - Howard Schraub
4: EX-4.1(B) Amended Consulting Agreement - George Furla
5: EX-4.1(C) Amended Consulting Agreement - V.T. Franzke
6: EX-4.1(D) Consulting Agreement - Mohamed Hadid
7: EX-4.1(E) Amended Consulting Agreement - Hendrix Bodden
8: EX-4.1(F) Consulting Agreement - Cliff Brune
9: EX-4.1(G) Amended Consulting Agreement - Ronald Mink
10: EX-4.1(H) Amended Consulting Agreement - Michael Sitrick
11: EX-4.1(I) Amended Consulting Agreement - Denise
Lescasse-Laurent
12: EX-4.1(J) Amended Consulting Agreement - Keith Lippert
13: EX-4.2 Form of Warrant
14: EX-5.1 Opinion of Naccarato & Associates
15: EX-23.1 Consent of Kpmg
--------------------------------------------------------------------------------
EX-4.1 · Advisory and Consulting Agreement
Number of Shares and Warrants
--------------------------------------------------------------------------------
4.1(a)
10,000,000
4.1(b)
10,000,000
4.1(c)
10,000,000
4.1(d)
8,000,000
4.1(e)
1,000,000
4.1(f)
240,000
4.1(g)
1,131,000
4.1(h)
1,800,000
4.1(i)
791,000
4.1(j)
1,650,000
Other
200,000
--------------------------------------------------------------------------------
Total
44,812,000
--------------------------------------------------------------------------------
http://www.secinfo.com/drdbh.223v.d.htm#1stPage
AGREEMENT, effective as of the 27th day of March, 2003, between Calypte Biomedical Corporation, a Delaware Corporation (the “Company”), of 1265 Harbor Parkway, Alameda, CA 94502, and Mohamed Hadid, 100 Carolwood, Los Angeles, CA 90077 (“Consultant”).
WHEREAS, THE Company desires the Consultant to provide consulting services to the Company pursuant hereto and Consultant is agreeable to providing such services.
NOW THEREFORE, in consideration of the premises and the mutual promises set forth herein, the parties hereto agree as follows:
1. Consultant shall serve as a consultant to assist the Company in general corporate activities including but not limited to the following areas:
(a) Research venues for foreign sales for the company’s products.
(b) Assist in the establishment of distribution partners in the Middle East and Russia for the company’s products.
(c) Provide support, including competitive information, for these regions.
2. Term: The Company shall be entitled to Consultant’s services for reasonable times when and to the extent requested by, and subject to the direction of Mr. Cataldo. The term of this Consulting Agreement began as of the date of this Agreement, and shall terminate on May 27, 2003.
Anthony J. Cataldo, Mohamed Hadid
SENETEK, PLC
By: /s/ Anthony J. Cataldo
-----------------------
Name: Anthony J. Cataldo
Title: Chairman and CEO
DATE OF TRANSACTION
August 31, 1999
SECURITIES SOLD
Under the terms and conditions of a Settlement agreement entered
into by Senetek PLC, Silvercreek Investments Ltd, Bomoseen
Investments Ltd, Elstree Holdings Ltd and Dandelion Investments Ltd
with Windsor Capital Management Ltd, Al-Sabah Trading and
Development Company, The Alana Group, Packard Ltd and Mohamed Hadid,
on April 13, 1999, Senetek agreed to issue an additional 625,000
Ordinary shares to Windsor Capital Management who in turn assigned
the right to receive 378,788 of the 625,000 Ordinary shares to
Wallington Investments Limited.
http://www.secinfo.com/$/SEC/Page.asp?P=929624-0-480-1-14-72578
PROMISSORY NOTE B
Los Angeles, California
April 13, 1999
FOR VALUE RECEIVED, the undersigned, MOHAMED HADID, does hereby promise to pay
to SENETEK PLC, a company organized under the laws of England, at its
office located at 620 Airpark Road, Napa, California, the following
amounts on or before the following dates:
· Download Table
Payment Date Payment Amount
----------------- --------------
May 3, 1999 $40,000
June 1, 1999 40,000
July 1, 1999 40,000
August 2, 1999 40,000
September 1, 1999 40,000
October 1, 1999 15,000
If any of the foregoing amounts shall not be paid in full on or prior to the
respective payment date set forth above, the unpaid portion shall bear
interest commencing on the respective payment date and continuing until
the unpaid amount shall have been paid in full (together with all
accrued interest thereon) at the rate of 10% per annum.
/s/ Mohamed Hadid
----------------------------------------
MOHAMED HADID
http://www.secinfo.com/$/SEC/Page.asp?P=950149-99-693-6-14-48825
Senetek PLC/ENG · 10-K · For 12/31/98 · EX-10.42 · p. 9
IN WITNESS WHEREOF, the parties hereto have entered into this
Agreement, or have caused this Agreement to be duly executed on their behalf by
their respective authorized representatives, as of the day and year first above
written.
SENETEK, PLC AL-SABAH TRADING AND
DEVELOPMENT COMPANY
By /s/ Frank J. Massino By /s/ Mohamed Hadid
------------------------------- --------------------------------------
Frank J. Massino Mohamed Hadid
Chief Executive Officer Authorized Signatory
WINDSOR CAPITAL MANAGEMENT, LTD. THE ALANA GROUP, LTD.
By /s/ Mohamed Hadid By /s/ Mohamed Hadid
------------------------------- --------------------------------------
Mohamed Hadid Mohamed Hadid
Authorized Signatory Authorized Signatory
PACKARD, LTD.
By /s/ Mohamed Hadid /s/ Mohamed Hadid
------------------------------- ----------------------------------------
Mohamed Hadid MOHAMED HADID
Authorized Signatory
SILVER CREEK INVESTMENTS, LTD. BOMOSEEN INVESTMENTS, LTD.
By /s/ Silver Creek Investments, Ltd. By /s/ Bomoseen Investments, Ltd.
------------------------------- --------------------------------------
Name: Name:
Title: Title:
ELSTREE HOLDING, LTD. DANDELION INVESTMENTS, LTD.
By /s/ Elstree Holding, Ltd. By /s/ Dandelion Investments, Ltd.
------------------------------- --------------------------------------
Name: Name:
Title: Title:
THE UNDERSIGNED HEREBY ACKNOWLEDGES THIS AGREEMENT FOR THE PURPOSES SPECIFIED IN
SECTIONS 7 AND 8 OF THIS AGREEMENT ONLY:
WALLINGTON INVESTMENTS
By /s/ Wallington Investments
-------------------------------
Name:
Title:
10/9/1 Michael Zwebner
6/27/2 Mohamad Hadid
12/9/2 Mohamed Hadid
6/27/96 Mohammed Hadid
Trans Continental Entertainment Group Inc
84 Names (Directors, Officers, Attorneys, Accountants, Bankers, Agents, et al.)
Last Filing Signatory
2/15/2 Alec Defrawy
3/8/2 Alexander H. Walker
3/8/2 Alexander H. Walker, III
10/21/98 Andreas O. Tobler
1/21/97 Anthony J. Georgelas
11/15/2 Anthony Ruben
11/15/2 C.W. Randell
2/15/2 Christine Hagan
3/25/2 Cohen, Rutherford, Blum and Knight pc
11/15/2 Cortes Randell
11/15/2 Cortes W. Randell
2/15/2 Court Randell
3/8/2 D. Mark White
11/20/96 Daniel Poitry
11/15/2 Dean Heller, Dean Heller
10/17/95 Douglas B. Silver
10/17/95 Douglas Silver
12/9/2 Edward Bell
7/23/98 Geoffrey A. Button
7/15/97 Geoffrey Button
12/9/2 Greg McDonald
12/9/2 Gregory T. McDonald
1/9/2 Herbert Becker
10/9/1 Herbert Lawrence Becker
11/20/96 Hugo Wyss
6/23/98 J. Michael Gettler
10/17/95 James H. Stanker
10/17/95 James Stanker
7/14/0 James T. Zelloe
12/29/0 James Zelloe
6/23/98 Jeff Shear
11/15/2 Jennifer L. Flammea
2/15/2 Jennifer L. Flammia
7/16/1 Jeremy Schuster
11/20/96 Joan Brown
12/9/2 Joan W. Randell
12/29/0 John Greenwood
3/5/97 John S. Stoppleman
5/29/97 Jules Marilus
10/17/95 Kenneth Baird
11/19/96 Khalid Alhegelan
1/9/2 Leo van den Herik
12/9/2 Louis J. Pearlman
11/19/96 Luiz Siqueira
1/21/97 Luiz Siqueria
1/12/1 Marilyn Foster
3/8/2 Mark O. Van Wagoner
12/9/2 Mark R.Tolner
11/18/3 Mark Tolner
11/20/96 Martin Thony, Bevollmachtigte
3/8/2 Merdinger, Fruchter, Rosen & Corso, PC
10/9/1 Michael Zwebner
3/5/97 Michail Danov
6/27/2 Mohamad Hadid
12/9/2 Mohamed Hadid
6/27/96 Mohammed Hadid
11/15/2 Neil Mauskapf
11/20/96 Nicholas de Smith
6/27/2 Paul S. Glover
1/21/97 Paul Sterbutzel
6/27/2 R. Edward Bell
12/9/2 Rafiah Kashmiri
2/15/2 Rafiah Kasmiri
2/15/2 Ray Edward Bell
2/15/2 Richard H. Tami
12/9/2 Richard J. Walk
3/15/3 Robert Alberty
5/29/97 Robert E. Nolan
11/20/96 Robert Sherpenhuijzen
7/16/1 Roger Serrero
1/9/2 Russell Pearman
6/27/96 S. Allan Kline
8/8/2 s/s Terri Bears
8/8/2 s/s Tom Weinard
10/17/95 Sandra R. Janer
1/12/1 Scott MacCaughern
11/20/96 Simon Brown
10/16/0 Theodore Georgelas
10/16/98 Theodore J. Georgelas
11/15/2 Thomas Weinard
5/23/2 Tom Weinard
7/7/3 Weinberg and Company, P.A.
12/13/96 Wesley N. Stark
3/5/97 Yolanda Herik
http://www.secinfo.com/$/SEC/Registrant.asp?CIK=741012&View=...
Paul Kessler and Bristol Asset Management
Skybridge
In May, 1998, significant capital was obtained through the efforts of Mr.
Paul Kessler and Bristol Asset Management,
http://www.secinfo.com/$/SEC/Page.asp?P=1063071-99-26-1-2-7248
Calypte Biomedical Corp · S-2/A · On 7/16/3 · p. 21
Mr. Paul Kessler, a Director of Bristol Investment Fund, Ltd., which was an
investor in a company with which Mr. Cataldo had been previously affiliated,
initially made the introduction of Mr. Cataldo to the Company as an existing
security holder of the Company who was concerned about the Company winding downits business affairs and its investment (holdings) in the Company. Thereafter,
Mr. Cataldo arranged for new financings, which were categorized under the
heading Recent Financings, primarily the Other Recent Financings. Mr. Cataldo
has disclaimed any affiliation or beneficial ownership with the individual
investors that comprise CIG. To the best of the Company`s knowledge, the
individual investors of CIG are not affiliated with each other. Mr. Cataldo was
a designee of the investors chosen in light of the tenuous financial condition
of the Company at the time of the new financing. He continues to actively pursue
raising the necessary capital to fund the Company`s on-going operations.
http://www.secinfo.com/$/SEC/Page.asp?P=1144204-3-3782-1-21-138099
"Mohamed Hadid"
Latest Filing: 3/28/3 as Signatory
--------------------------------------------------------------------------------
As: Signatory (Director, Officer, Attorney, Accountant, Banker, Agent, etc.)
List All Filings as Signatory
Search Recent Filings (as Signatory) for "Mohamed Hadid"
DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS, AND CONTROL PERSONS
The members of the Board of Directors of the Company serve until the next annual
meeting of the stockholders, or until their successors have been elected. The
officers serve at the pleasure of the Board of Directors, but may be removed by
a vote of the shareholders holding a majority of shares outstanding and entitled
to vote.
There are no agreements for any officer or director to resign at the request of
any other person, and none of the officers or directors named below are acting
on behalf of, or at the direction of, any other person.
Information as to the directors and executive officers of the Company is as
follows:
=============================================================================================
Name/Address Age Position
================================= =========== ===================================
Mohamed Hadid
5757 Wilshire Blvd., Suite 124
Los Angeles, CA 90036 51 Chairman/Director
--------------------------------- ----------- -----------------------------------
Anthony Cataldo
63 Northeast Village Rd.
Concord, N.H. 03301 48 President/Director
--------------------------------- ----------- -----------------------------------
Jeremy Schuster
5757 Wilshire Blvd. Suite 124
Los Angeles, CA 90036 36 Chief Operating Officer/Director
--------------------------------- ----------- -----------------------------------
Roland Joffe
2854 Roscomare Road
Los Angeles, CA 90077 54 Director
--------------------------------- ----------- -----------------------------------
Marion Dougherty
c/o Gary S. Kleinman Acctg. Corp.
10340 Santa Monica Blvd.
Los Angeles, CA 90025 76 Director
--------------------------------- ----------- -----------------------------------
Jean Claude Van Damme
1801 Avenue of the Stars #308
Los Angeles, CA 90067 39 Director
--------------------------------- ----------- -----------------------------------
James Zelloe
7601 Lewinsville Road, #250
McLean, VA 22102 40 Director
--------------------------------- ----------- -----------------------------------
Thom Mount
6363 Sunset Blvd.
Los Angeles, CA 90028 51 Director
--------------------------------- ----------- -----------------------------------
Marilyn Foster Staubitz
5757 Wilshire Blvd., Suite 124
Los Angeles, CA 90036 34 Director
--------------------------------- ----------- -----------------------------------
Mohamed Hadid - Chairman.
The Company's Chairman, Mr. Mohamed Hadid, is also Chairman of Sector
Communications, Inc., and Vice-Chairman of First Miracle Group, Inc. In
addition, Mr. Hadid serves as Chairman of Hadid Development Company and was
formerly Managing Director of Emerald Capital Corporation.
Mr. Hadid holds a number of senior management positions with a portfolio of
companies, including being the Founding Co-Chairman of Global Communications
Group, and Co-Founder and Director of Voice Powered Technology. Mr. Hadid
formerly was the largest single owner of the Ritz Carlton Hotels, with
properties in Aspen, Colorado; Washington, D.C.; Houston, Texas; and New York.
Mr. Hadid has been responsible for the development of over seven million square
feet of commercial office buildings in the greater Washington, D.C. area, with
total value estimated to be in excess of U.S. $2.7 billion.
A former director of Adams National Bank and Advisory Board Director of National
Enterprise Bank, Mr. Hadid was responsible for structuring over U.S.
$200,000,000.00 in financing for smallcap and emerging public companies. Mr.
Hadid holds a Bachelor of Science degree from North Carolina State University,
and attended graduate school at Massachusetts Institute of Technology.
Anthony Cataldo - President/Director.
Mr. Anthony Cataldo is the President of The Entertainment Internet, Inc., and is
CEO of First Miracle Group, Inc., an independent and diversified film company
with a unique corporate structure based on strategic and exclusive alliances
with high quality content producers, including Long Road Films and Emmett/Furla
Films. As part of First Miracle Group's recently-announced exclusive development
deal with Jean Claude Van Damme's Long Road Films, all worldwide revenues
generated by films will be shared on a 50/50 basis between the two entities.
http://www.secinfo.com/$/SEC/Page.asp?P=1063071-99-26-1-2-7248
"Mohamed Hadid" has been a Signatory for/with the following 4 Registrants:
Trans Continental Entertainment Group Inc [ formerly Options Talent Group ]
Skybridge Wireless Inc [ formerly Entertainment Internet Inc ]
Senetek PLC/ENG
Calypte Biomedical Corp
"Mohamed Hadid" has been a Signatory for/with the following 4 Registrants:
Trans Continental Entertainment Group Inc [ formerly Options Talent Group ]
Skybridge Wireless Inc [ formerly Entertainment Internet Inc ]
Senetek PLC/ENG
Calypte Biomedical Corp
The Entertainment Internet, Inc. Elects Michael Zwebner To Board of Directors
...
Tony Cataldo Resigns Position as President of The Entertainment Internet, Inc. (TEI)
...
The Entertainment Internet, Inc. Elects Michael Zwebner To Board of Directors
Business/Entertainment Editors
LOS ANGELES--(BUSINESS WIRE)--June 28, 2000--The Entertainment Internet, Inc. (TEI) (EQS:EINI) confirmed today the election of Michael J. Zwebner to its Board of Directors.
Zwebner currently serves as the Chairman of the Board of Directors of Talk Visual Corporation (OTCBB:TVCP) and earlier offered to assist TEI in furthering the turnaround plan undertaken last year.
TEI Co-chairman Mohamed Hadid said, "Election of Mr. Zwebner represents another step forward in the restructuring of the Corporation's business plans."
Prior to his election, Zwebner conducted due diligence inquiries that included review of the corporation's capital structure, prior transactions, current commitments, and interviews with subsidiary corporation staff. Throughout the due diligence process, Zwebner retained his belief that TEI has not yet realized more than a fraction of its potential and that he could assist in moving TEI toward its profit-making goals.
TEI Chief Operating Officer Jeremy Schuster said, "Mr. Zwebner understands the roles of e-commerce and strategic relationships in our new business model; his years of marketing experience can only complement the initiative we undertook last July. The Board welcomes Mr. Zwebner and looks forward to his continued involvement."
Currently, TEI's subsidiary operates the Castnet.com(TM) electronic communities that help actors, casting directors and talent agents electronically communicate with each other and receive instant responses to specialized data searches. TEI's Castnet.com(TM) systems provide users with access to a sophisticated virtual private network that offers security, performance and reliability matched to the needs of the entertainment industry.
TEI's database resources and Castnet.com(TM) services are used by more than 300 casting directors, 185 guild franchised agencies and 32,000 actors across the United States, with additional subscribers being added daily. The Castnet.com sites have the approval of the Producers Guild of America.
http://snipurl.com/3uj4
Tony Cataldo Resigns Position as President of The Entertainment Internet, Inc. (TEI)
LOS ANGELES, Jan. 14 /PRNewswire/ -- The Entertainment Internet, Inc. (TEI) (OTC Bulletin Board: EINIE) announced today that the resignation of Mr. Tony Cataldo, earlier offered in conjunction with cancellation of a proposed TEI-Miracle Entertainment (OTC Bulletin Board: MVEE) merger, was accepted by TEI's Board of Directors. Mr. Cataldo served as TEI President and a member of its Board of Directors. TEI Chief Operating Officer Jeremy Schuster said TEI and Miracle Entertainment will continue to work together through earlier-executed casting agreements.
December, 1999
http://snipurl.com/3uja
The Entertainment Internet Files to Eliminate Prior Debts, Continues Castnet.com Services as Host
LOS ANGELES--(BUSINESS WIRE)--Nov. 24, 2000--The Entertainment Internet Inc. (TEI) (EQS:EINI) filed for reorganization to eliminate millions of dollars in unsecured and other debts incurred by prior management and to protect it from creditors while it continues to operate the Castnet.com(TM) Web sites it developed.
The filing is expected to rid the company and its subsidiary of several classes of claims and debts and to recover monies paid for certain claims and settlements during the past 90 days, while present management frames a reorganization plan.
According to the company, the Castnet.com(TM) Web sites are now owned by its principal lender and are operated through an arrangement which allows the company continued but reduced funding. The lender recognizes that Web site value is impaired or negated by interruption of service and is allowing the company to continue to operate and host the Castnet.com(TM) Web sites on its behalf.
Subscribers to the Castnet.com(TM) services, like other creditors, will receive appropriate notices as the case proceeds, but are assured that the company has taken this decisive action to rid itself of suffocating debt so that it can better serve as an electronic community host.
Strategic Marketing V.P. Rick La Fond said: "We will continue to serve the production, casting, and acting communities while outside counsel assists us in shedding the debt amassed by prior management. While our detractors and competitors may make contrary statements, it will be business as usual for Castnet.com(TM) and TEI's dedicated staff."
TEI offices will be closed through Monday in observance of the Thanksgiving holiday.
http://snipurl.com/3uj7
Tony Cataldo Resigns Position as President of The Entertainment Internet, Inc. (TEI)
LOS ANGELES, Jan. 14 /PRNewswire/ -- The Entertainment Internet, Inc. (TEI) (OTC Bulletin Board: EINIE) announced today that the resignation of Mr. Tony Cataldo, earlier offered in conjunction with cancellation of a proposed TEI-Miracle Entertainment (OTC Bulletin Board: MVEE) merger, was accepted by TEI's Board of Directors. Mr. Cataldo served as TEI President and a member of its Board of Directors. TEI Chief Operating Officer Jeremy Schuster said TEI and Miracle Entertainment will continue to work together through earlier-executed casting agreements.
CYPT Consulting Agreement - Mohamed Hadid
Calypte Biomedical Corp · S-8 · On 3/28/3 · EX-4.1(D)
http://www.secinfo.com/drdbh.223v.9.htm?Find=Hadid&Line=42#1stPage
Exhibit 4.1(d)
CONSULTING AGREEMENT
AGREEMENT, effective as of the 27th day of March, 2003, between Calypte Biomedical Corporation, a Delaware Corporation (the “Company”), of 1265 Harbor Parkway, Alameda, CA 94502, and Mohamed Hadid, 100 Carolwood, Los Angeles, CA 90077 (“Consultant”).
WHEREAS, THE Company desires the Consultant to provide consulting services to the Company pursuant hereto and Consultant is agreeable to providing such services.
NOW THEREFORE, in consideration of the premises and the mutual promises set forth herein, the parties hereto agree as follows:
1. Consultant shall serve as a consultant to assist the Company in general corporate activities including but not limited to the following areas:
(a) Research venues for foreign sales for the company’s products.
(b) Assist in the establishment of distribution partners in the Middle East and Russia for the company’s products.
(c) Provide support, including competitive information, for these regions.
2. Term: The Company shall be entitled to Consultant’s services for reasonable times when and to the extent requested by, and subject to the direction of Mr. Cataldo. The term of this Consulting Agreement began as of the date of this Agreement, and shall terminate on May 27, 2003.
3. Reasonable travel and other expenses necessarily incurred by Consultant to render such services, and approved in advance by the Company, shall be reimbursed by the Company promptly upon receipt of proper statements, including appropriate documentation, with regard to the nature and amount of those expenses. Those statements shall be furnished to the Company monthly at the end of each calendar month in the Consulting Period during which any such expenses are incurred. Company shall pay expenses within fifteen (15) business days of the receipt of a request with appropriate documentation.
4. In consideration for the services to be performed by Consultant, the Consultant will receive a warrant to purchase eight million, (8,000,000) shares of the common stock of the Company at an exercise price of $0.025 cents per share. The warrant expires on June 27, 2003.
5. The consultant will provide to Calypte’s Executive Chairman a written report of services rendered and results thereof within 30 days of the conclusion of this contract.
6. It is the express intention of the parties that the Consultant is an independent contractor and not an employee or agent of the Company. Nothing in this agreement shall be interpreted or construed as creating or establishing the relationship of employer and employee between the Consultant and the Company. Both parties acknowledge that the Consultant is not an employee for state or federal tax purposes. The Consultant shall retain the right to perform services for others during the term of this agreement.
6.1 The consulting services shall not involve and the consultant is not engaged in services in connection with the offer or sale of securities in a capital-raising transaction for Calypte, and further, the consultant does not and will not directly or indirectly promote or maintain a market for Calypte’s securities.
7. Neither this agreement nor any duties or obligations under this agreement may be assigned by the Consultant without the prior written consent of the Company.
8. This agreement may be terminated upon ten (10) days written notice by the Company. Notwithstanding any termination, the compensation, as outlined in Section 4, shall be earned in full by the Consultant upon execution of this agreement.
9. Any notices to be given hereunder by either party to the other may be given either by personal delivery in writing or by mail, registered or certified, postage prepaid with return receipt requested. Mailed notices shall be addressed to the parties at the addressed appearing in the introductory paragraph of this agreement, but each party may change the address by written notice in accordance with the paragraph. Notices delivered personally will be deemed communicated as of actual receipt; mailed notices will be deemed communicated as of two days after mailing.
10. This agreement supersedes any and all agreements, either oral or written, between the parties hereto with respect to the rendering of services by the Consultant for the Company and contains all the covenants and agreements between the parties with respect to the rendering of such services in any manner whatsoever. Each party to
this agreement acknowledges that no representations, inducements, promises, or agreements, orally or otherwise, have been made by any party, or anyone acting on behalf of any party, which are not embodied herein, and that no other agreement, statement, or promise not contained in this agreement shall be valid or binding. Any modification of this agreement will be effective only if it is in writing signed by the party to be charged.
11. This agreement will be governed by and construed in accordance with the laws of the State of California, without regard to its conflicts of laws provisions; and the parties agree that the proper venue for the resolution of any disputes hereunder shall be Alameda County, California.
12. For purposes of this Agreement, Intellectual Property will mean (i) works, ideas, discoveries, or inventions eligible for copyright, trademark, patent or trade secret protection; and (ii) any applications for trademarks or patents, issued trademarks or patents, or copyright registrations regarding such items. Any items of Intellectual Property discovered or developed by the Consultant (or the Consultant’s employees) during the term of this Agreement will be the property of the Consultant, subject to the irrevocable right and license of the Company to make, use or sell products and services derived from or incorporating any such Intellectual Property without payment of royalties. Such rights and license will be exclusive during the term of this Agreement, and any extensions or renewals of it. After termination of this Agreement, such rights and license will be nonexclusive, but will remain royalty-free. Notwithstanding the preceding, the textual and/or graphic content of materials created by the Consultant under this Agreement (as opposed to the form or format of such materials) will be, and hereby are, deemed to be “works made for hire” and will be the exclusive property of the Company. Each party agrees to execute such documents as may be necessary to perfect and preserve the rights of either party with respect to such Intellectual Property.
13. The written, printed, graphic, or electronically recorded materials furnished by the Company for use by the Consultant are Proprietary Information and are the property of the Company. Proprietary Information includes, but is not limited to, product specifications and/or designs, pricing information, specific customer requirements, customer and potential customer lists, and information on Company’s employees, agent, or divisions. The Consultant shall maintain in confidence and shall not, directly or indirectly, disclose or use, either during or after the term of this agreement, any Proprietary Information, confidential information, or know-how belonging to the Company, whether or not is in written form, except to the extent necessary to perform services under this agreement. On termination of the Consultant’s services to the Company, or at the request of the Company before termination, the Consultant shall deliver to the Company all material in the Consultant’s possession relating to the Company’s business.
14. The obligations regarding Proprietary Information extend to information belonging to customers and suppliers of the Company about which the Consultant may have gained knowledge as a result of performing services hereunder.
15. The Consultant shall not, during the term of this agreement and for a period of one year immediately after the termination of this agreement, or any extension of it, either directly or indirectly (a) for purposes competitive with the products or services currently offered by the Company, call on, solicit, or take away any of the Company’s customers or potential customers about whom the Consultant became aware as a result of the Consultant’s services to the Company hereunder, either for the Consultant or for any other person or entity, or (b) solicit or take away or attempt to solicit or take away any of the Company’s employees or consultants either for the Consultant or for any other person or entity.
16. The Company will indemnify and hold harmless Consultant from any claims or damages related to statements prepared by or made by Consultant that are either approved in advance by the Company or entirely based on information provided by the Company.
Consultant:
Mohamed Hadid
Company:
Calypte Biomedical Corporation
/s/ Mohamed Hadid
--------------------------------------------------------------------------------
By:
/s/ Richard Brounstein
--------------------------------------------------------------------------------
Richard Brounstein
Executive Vice President & CFO
Ticker:: CYPT Exchange: OTC Bulletin Board
Agreement for Commitment to Purchase Aggregate of
$10,000,000 of 5% Promissory Notes
Securities: 5% Notes, each with 12 month term (the "Notes")
of the Issuer
Issuer: Calypte Biomedical Corporation (the "Issuer")
------
Purchaser: Marr Technologies, B.V.
---------
Commitment Amount: $10,000,000
-----------------
Use of Proceeds: General Corporate Purposes
---------------
I. Terms of Note Issuance
a. Note Issuance: Beginning on the First Availability Date and continuing through the Availability Period (each as defined in Section III.c.)of this agreement, the Issuer may issue Notes, in its sole discretion (each, a "Note"), which the Purchaser shall be obligated to accept, with an aggregate total not to exceed the Commitment Amount.
b. Issuance Notice: The Issuer shall indicate its intention to issue a Note by delivering to the Purchaser an Issuance Notice (each, an "Issuance Notice") via facsimile transmission. The Issuance Notice shall specify:
(i) The amount of the Note (the "Note Amount");
(ii) The date on which the Note is to be effective and funded, which shall be no sooner than 4 business days from the date of the Issuance Notice. If the Issuer wishes the Note to be funded on the fourth business day, the Issuance Notice must be delivered to the Purchaser and such receipt confirmed,before 8:30 a.m. ET.
(iii) A form of Issuance Notice is attached hereto as Exhibit B.
c. Note Amount: The Note Amount shall be a minimum of $500,000 in any single issuance. The maximum Note Amount in the first month following the First Availability Date shall be $1,500,000 and,should the conditions regarding listing of the Company's common stock described in Section III.b. herein not be met, such Note will become due and payable on April 30, 2004.
II. Settlement
a. Settlement: Within 24 hours of the Issuer's transmission of the Issuance Notice to the Purchaser, Purchaser shall
confirm receipt thereof. Once the Purchaser confirms the
receipt of the Issuance Notice, Purchaser shall have 3
business days in which to purchase the Note by wire
transfer of immediately available funds to the Issuer's
designated account. At the election of either party, an
escrow agent may be used.
b. Note Agreement: Each Note issued pursuant to an Issuance
Notice under this Agreement shall be evidenced by a Note
substantially in the form of Exhibit A hereto and shall be
executed by authorized representatives of both Purchaser
and Issuer.
c. Term of Note. Except as noted in Section I.c. with respect
to any Note issued during the first month following the First Availability Date, Each Note issued under the terms of this Agreement shall have a term of 12 months and shall be repaid upon maturity by wire transfer of immediately available funds to the Purchaser's designated account.
d. Interest. Interest shall accrue at 5% per annum on any Notes issued under the terms of this Agreement and shall be
paid in cash upon the maturity of the Note.
III. General Conditions
a. Effective Date: The Effective Date of this agreement shall
be the date on which the authorized representatives of the
Issuer and Purchaser shall have signed this Agreement.
b. Term of Agreement. This agreement shall terminate on May
31, 2005. Notwithstanding the preceding sentence, this Agreement shall terminate on March 31, 2004 if, at that date, Issuer shall not have its common stock, $0.03 par value, listed on either the American Stock Exchange, the New York Stock Exchange, the Nasdaq National Market or Nasdaq Small Cap Market.
c. First Availability Date and Availability Period. The
earliest date upon which the Issuer may issue an Issuance
Notice under the terms of this agreement is February 28,
2004 (the "First Availability Date"). Subject to the provisions of Section 1.c. herein, Issuer may issue an Issuance Notice on any date thereafter through and including May 31, 2004. The period from February 28, 2004 through May 28, 2004, inclusive, is defined as the "Availability Period".
d. Subsequent Financings: During the term of this Agreement,
Issuer will notify Purchaser of all offerings for equity
financing which it may undertake. Equity financings shall,
for the purposes of this Agreement, be defined as cash received by Issuer from the sale of Issuer's common stock,
$0.03 par value, or such other equity security as it may
offer from time to time, for cash, specifically excluding
cash received from the exercise of currently outstanding or
subsequently granted options or warrants issued to
employees, consultants, or other parties for services or in
lieu of cash for services or for intellectual property
rights.
i. Issuer will grant Purchaser the right of first refusal to
participate in any such subsequent equity financings on the
same key terms and conditions, which shall include the dollar investment amount or number of shares to be urchased,pricing, number of warrants and their terms, if any, registration rights and fees, as applicable to the subject offer. Purchaser shall inform Issuer of its decision to participate in any subsequent equity financing within two business days of notice from Issuer.
ii. Regardless of Purchaser's election to participate in any
such subsequent equity financings, the Total Note Purchase
Commitment under this Agreement shall be decreased dollar
for dollar by the net amount of such subsequent equity
financing completed by Issuer.
d. Issuance of Warrant. As fee for the loan commitment evidenced by this Agreement, Issuer agrees to issue, on the Effective Date, a warrant to purchase 375,000 shares of its common stock, $0.03 par value, at a price of $0.80 per share. The warrant shall be immediately exercisable and shall have a term of two years from the Effective Date. The Warrant shall be issued to:
Boodle Hatfield.
61 Brook Street
London W1K 4BL
A form of warrant is attached as Exhibit C.
e. Non-utilization of Commitment. No utilization of this Note
facility may be made if, at the time the Issuance Notice is
tendered to Purchaser or at the time the Note is issued, an event
of default or an event which, with the giving of notice or lapse of time or both, would constitute an event of default (the "Event of Default") has occurred and is continuing or would result from such utilization of this facility.
f. Events of Default. Purchaser may, without prejudice to its other rights hereunder, terminate its obligation to purchase the Notes and declare all outstanding amounts owing to Purchaser pursuant to Notes issued under this Agreement, together with all accrued interest and such other payments payable under this Agreement, immediately due and payable at any time after any of the following events shall have occurred:
i. The Issuer defaults in the due performance of observance of any of its obligations under this agreement and, if such
default is, in the opinion of the Purchaser, capable of remedy, such default shall not have been remedied within 14
days of the Purchaser notifying the Issuer of such default;
or
ii. Any judgment or order of a court of competent jurisdiction in an amount exceeding $10,000 made against the Issuer is not stayed or complied with within 21 days of an
encumbrancer takes possession of the whole or part of the
assets, rights, or revenues of the Issuer or a distress or
other process is levied or enforced upon any of the assets,
rights or revenues of the Issuer and is not discharged
within 21 days; or
iii. The Issuer is adjudicated and found insolvent or any step is taken or proceedings are commenced for the winding-up,
administration, liquidation, restructuring or dissolution
of the Issuer of for the appointment of a liquidator, trustee in bankruptcy, receiver or similar officer in respect of the Issuer or the whole or any part of its assets, rights, or revenues; or
iv. The Issuer stops or suspends payment of its debts incurred
subsequent to September 30, 2003, as summarized in Exhibit
D, or is, or has been deemed to be, unable to, or admits
inability to, pay its debts as they come due or it commences negotiations with one or more if its creditors with a view to the general rescheduling of all or any of its debts or proposes or enters into any composition or other arrangement for the benefit of its creditors generally, or of any class thereof; or
v. Except with respect to a Note issued within the month
following the First Availability Date, the common stock of
the Issuer ceases to be listed on a recognized stock
exchange in the United States of America; or
vi. Any other event occurs or circumstance arises which is
likely to have a material adverse effect on the business or
financial condition of the Issuer.
This agreement is executed and binding as of this 13th day of November 2003.
Calypte Biomedical Corporation
("Issuer") A Delaware Corporation
By: /s/ Jay Oyakawa
----------------------------------------
Title: President and CEO
--------------------------------------
Marr Technologies, B.V.
("Purchaser")
By: /s/ J.K. Basnet
----------------------------------------
Title: Authorised Signatory
-------------------------------------
Agreement for Commitment to Purchase Aggregate of $10,000,000 of 5% Promissory Notes
November 13, 2003
Calypte Biomedical Corporation
------------------------------
Ticker: CYPT
Exchange: OTC Bulletin Board
Agreement for Commitment to Purchase Aggregate of
$10,000,000 of 5% Promissory Notes
Securities: 5% Notes, each with 12 month term (the "Notes")
---------- of the Issuer
Issuer: Calypte Biomedical Corporation (the "Issuer")
------
Purchaser: Marr Technologies, B.V.
---------
Commitment Amount: $10,000,000
-----------------
Use of Proceeds: General Corporate Purposes
---------------
This agreement is executed and binding as of this 13th day of November 2003.
Calypte Biomedical Corporation
("Issuer") A Delaware Corporation
By: /s/ Jay Oyakawa
----------------------------------------
Title: President and CEO
---------------------------
Marr Technologies, B.V.
("Purchaser")
By: /s/ J.K. Basnet
----------------------------------------
Title: Authorised Signatory
..................................................
Janak K. Basnet, a director of Marr Technologies Limited and Marr Group Holdings Limited, has sole voting and dispositive power with respect to 2,432,095 or approximately 1.8% of the 136,381,689 shares of common stock of the Company outstanding.
Janak K. Basnet, Rosewood Trust - a director of Marr Technologies Limited and Marr Group Holdings Limited,...
Rosewood Trust
In a development which we had not anticipated as recently as the January edition of this newsletter, various clients of Janak Basnet, who was then managing Lorne House Management Limited, asked him to establish his own corporate and trust management company. This he has done, under the name of Rosewood Trust Limited. Ronald Buchanan and he jointly signed letters to existing clients of LHM, suggesting which clients might appropriately stay put and which might wish to change to Rosewood. Nearly all of them have agreed to our suggestions.The partition has been wholly amicable. Janak Basnet remains on the board of Lorne HouseTrust and Rosewood has leased the north wing of Lorne House. Rosewood can still be reached on Lorne House numbers but their new, exclusive voice number is +44/0 1624824567, fax ++825439.
Rosewood Trust Limited
Lorne House North
Castletown
Isle of Man
IM9 1AZ
Tel: +44 (0) 1624 824567
Marat R. Safin is a British citizen. Mr. Safin's principal business is serving as Director of Marr Group Holdings Limited.
The address of his principal business and its principal office is
Suite 240,
Barkly Wharf,
Le Caudan Waterfront,
Port Louis, Mauritius.
Marr Group Holdings Limited is incorporated in Mauritius.
Marr Group Holdings Limited's principal business is as a holding company.
The address of its principal office is
Suite 240, Barkly Wharf,
Le Caudan Waterfront,
Port Louis, Mauritius.
Marr Technologies Limited is incorporated in Mauritius.
Marr Technologies Limited's principal business is as a holding company.
The address of its principal office is
Suite 240, Barkly Wharf,
Le Caudan Waterfront,
Port Louis, Mauritius
Marr Technologies NV is incorporated in the Netherlands Antilles. Marr Technologies NV's principal business is as a holding company.
The address of its principal office is
Van Engelenweg 21 A, Curacao,
Netherlands Antilles.